Navigation Links
Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum
Date:3/31/2009

- Covance's periapproval services experts to discuss REMS consulting, design and implementation -

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) experts will present key insights on risk management and risk evaluation and mitigation strategies (REMS) at the 5th Annual CBI Bio/Pharmaceutical Drug Safety Forum from March 30-31, 2009 in Washington, D.C.

Glynis Neagle, M.D., Covance's vice president of medical affairs for periapproval services will chair the two-day event, designed to examine safety and risk initiatives and provide in-depth coverage on REMS implementation and follow-up.

On Monday, March 30, Edgar H. Adams, ScD, Covance's executive director of epidemiology will present "Risk Minimization Strategies for REMS Development." This presentation will discuss how the Food and Drug Administration Amendments Act (FDAAA) of 2007 has impacted drug development by mandating REMS and enforcing penalties of up to $10 million dollars to companies who fail to adhere.

Focusing on new drug development, Dr. Adams will also discuss the importance of thoroughly understanding a new drug's potential risk prior to approval to avoid delay due to mandated REMS. Full understanding of risk enables the development of a REMS that balances benefit, risk and burden so that patient access is maximized while risk and undue burden are minimized, according to Dr. Adams.

"Pharmaceutical and biotechnology companies are facing a variety of potential compliance challenges as a result of FDAAA," said Dr. Neagle. "With a focus on REMS across drug development, new risk management solutions need to be designed to help sponsors avoid costly delays that may result from the FDA's increased scrutiny of drugs not currently governed by safety restrictions."

Covance Periapproval Services offers a broad spectrum of post-marketing services, ranging from Phase IIIb/IV clinical studies to registries and observational studies, risk management, epidemiology, and product safety services. As a leader in the design and implementation of Risk Evaluation and Mitigation Strategies (REMS), Covance's periapproval services team offers unique tools and methodologies specifically designed to meet clients' post-approval goals.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Covance, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the Barclays Capital Global Healthcare Conference
2. Covance Elects Bradley T. Sheares to Companys Board of Directors
3. Covance to Present at the 2009 UBS Global Healthcare Services Conference
4. Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
5. Covance Reports Fourth Quarter and Full-Year 2008 Results
6. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2008 Financial Results Conference Call
8. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
9. Covance to Present at the Credit Suisse 2008 Healthcare Conference
10. Covance and Lilly Enter Into a Strategic R&D Collaboration
11. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Phoenix, announced today that it will soon begin franchising throughout the U.S. starting ... mission to help bring the practice of meditation mainstream. Current Meditation will be ...
(Date:2/23/2017)... , ... ... the perfect opportunity for the nation to come together to ... basketball bracket – with its favorite fruit – apples! To ... apple lovers to join the “Apple Madness” bracket tournament – ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today ... efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three ... enrolling children across the United States. , “There are currently no approved drugs ...
(Date:2/23/2017)... ... 2017 , ... Carlos Gutierrez has lived his spiritual life hardly ... which is the purpose of everyone in this universe. As Gutierrez sees the need ... Press) attempts to guide readers to expand one’s spiritual life. , “Our Spiritual Truths” ...
(Date:2/22/2017)... ... ... Gevir, a New Zealand-based company that focuses on developing powder and capsule ... Amazon.com, the world’s largest online retailer. , The company was founded in ... treatment for Shelley’s Multiple Sclerosis, which she’d been diagnosed with at 28 years old. ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... The fast-growing cannabis market is expected to create ... According to the 2017 Legal Marijuana Outlook, published by New ... jobs by 2020, with an implied growth rate of more ... accelerating pace of cannabis legalization is considered as the main ... will further create more business ventures and boost the economy. ...
(Date:2/23/2017)... New York , February 23, 2017 ... Cardiac Holter Monitor Market are GE Healthcare, Koninklijke Philips ... of about 48% in the global market in 2015. ... the two key factors assessed to be aiding these ... Market Research states that the players in the global ...
(Date:2/23/2017)... MILFORD, Mass. , Feb. 23, 2017 /PRNewswire/ ... leading partner to global in vitro diagnostics manufacturers ... webinar series titled "Catalyzing Implementation of NGS-Based Tests" ... on March 30, 2017 at 11am Eastern Standard ... series is to highlight the need for improved ...
Breaking Medicine Technology: